Rein Therapeutics, Inc. (RNTX) — 8-K Filings

8-K Filings (34)

• 8-K Filing — May 4, 2026
• Rein Therapeutics Terminates Material Agreement — Dec 11, 2025 Risk: medium
  Rein Therapeutics, Inc. filed an 8-K on December 11, 2025, to report the termination of a material definitive agreement. The filing does not specify the other p
• 8-K Filing — Nov 3, 2025
• Rein Therapeutics Enters Material Agreement, Discloses Financial Obligations — Oct 24, 2025 Risk: medium
  Rein Therapeutics, Inc. announced on October 23, 2025, that it entered into a material definitive agreement. The company also disclosed the creation of a direct
• Rein Therapeutics Files 8-K — Oct 9, 2025 Risk: low
  Rein Therapeutics, Inc. filed an 8-K on October 9, 2025, reporting other events and financial statements. The company, formerly known as Aileron Therapeutics, I
• Rein Therapeutics Files 8-K — Sep 22, 2025 Risk: medium
  Rein Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting an event on September 16, 2025. The filing indicates a change in the company's status or o
• Rein Therapeutics Enters Material Agreement, Faces Financial Obligations — Sep 9, 2025 Risk: medium
  Rein Therapeutics, Inc. entered into a Material Definitive Agreement on September 8, 2025. This agreement creates a direct financial obligation for the company.
• Rein Therapeutics Files 8-K — Aug 19, 2025 Risk: low
  Rein Therapeutics, Inc. filed an 8-K on August 19, 2025, reporting other events and financial statements. The company, formerly known as Aileron Therapeutics, I
• Rein Therapeutics Files 8-K on Agreements and Equity Sales — Jul 30, 2025 Risk: medium
  Rein Therapeutics, Inc. filed an 8-K on July 30, 2025, reporting on several key events. These include entering into a material definitive agreement, creating a
• Rein Therapeutics, Inc. Files 8-K — Jul 23, 2025 Risk: low
  On July 23, 2025, Rein Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's name from Aileron Therapeutics, Inc. to Rein Thera
• Rein Therapeutics Files 8-K — Jul 11, 2025 Risk: low
  Rein Therapeutics, Inc. filed an 8-K on July 11, 2025, reporting events that occurred on July 8, 2025. The filing indicates amendments to its Articles of Incorp
• Rein Therapeutics to be Acquired by 03 Life Sciences — Jun 24, 2025 Risk: medium
  Rein Therapeutics, Inc. announced on June 24, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expec
• Rein Therapeutics to be Acquired by 03 Life Sciences — Jun 12, 2025 Risk: medium
  Rein Therapeutics, Inc. announced on June 10, 2025, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is expec
• Rein Therapeutics Files 8-K on Operations and Financials — May 15, 2025 Risk: low
  Rein Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial stateme
• Rein Therapeutics Files 8-K on Agreements and Equity Sales — Apr 22, 2025 Risk: medium
  Rein Therapeutics, Inc. (formerly Aileron Therapeutics, Inc.) filed an 8-K on April 22, 2025, reporting on a material definitive agreement, unregistered sales o
• Rein Therapeutics Changes Auditors Amidst Reporting Disagreement — Apr 17, 2025 Risk: medium
  Rein Therapeutics, Inc. announced on April 16, 2025, a change in its certifying accountant. The company has dismissed PricewaterhouseCoopers LLP and engaged Ern
• Rein Therapeutics Files 8-K with Corporate Updates — Jan 10, 2025 Risk: low
  Rein Therapeutics, Inc. filed an 8-K on January 10, 2025, reporting an amendment to its articles of incorporation or bylaws, other events, and financial stateme
• Aileron Therapeutics Files 8-K on Financials — Nov 14, 2024 Risk: low
  Aileron Therapeutics, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing also includes financial
• Aileron Therapeutics Files 8-K — Aug 21, 2024 Risk: low
  Aileron Therapeutics, Inc. filed an 8-K on August 21, 2024, reporting on matters submitted to a vote of security holders and financial statements/exhibits. The
• Aileron Therapeutics Files 8-K on Financials — Aug 14, 2024 Risk: low
  Aileron Therapeutics, Inc. filed an 8-K on August 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Aileron Therapeutics Files 8-K: Material Definitive Agreement — Jul 26, 2024 Risk: medium
  Aileron Therapeutics, Inc. announced on July 26, 2024, that it entered into a Material Definitive Agreement. The filing also includes other events and financial
• Aileron Therapeutics Files 8-K on Shareholder Nominations — Jun 5, 2024 Risk: medium
  Aileron Therapeutics, Inc. filed an 8-K on June 5, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. The filing
• Aileron Therapeutics: CMO Departs, New Interim CMO Appointed — May 16, 2024 Risk: medium
  Aileron Therapeutics, Inc. announced on May 15, 2024, the departure of Dr. Christopher P. Miller as Chief Medical Officer and the appointment of Dr. Andrew R. A
• Aileron Therapeutics Files 8-K — May 15, 2024 Risk: low
  Aileron Therapeutics, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition, as well as financial statements and exh
• Aileron Therapeutics Files 8-K — May 1, 2024 Risk: low
  Aileron Therapeutics, Inc. filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition, as well as other events. The filing does
• Aileron Therapeutics Files 8-K — Apr 15, 2024 Risk: low
  Aileron Therapeutics, Inc. filed an 8-K on April 15, 2024, reporting on its results of operations and financial condition, and including financial statements an
• Aileron Therapeutics Reports Leadership and Compensation Changes — Mar 29, 2024 Risk: medium
  On March 25, 2024, Aileron Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a
• Aileron Therapeutics Files 8-K with Board and Compensation Updates — Mar 15, 2024 Risk: medium
  Aileron Therapeutics, Inc. announced on March 11, 2024, changes in its board of directors and executive compensation arrangements. The filing also includes fina
• Aileron Therapeutics Appoints New Chief Medical Officer — Mar 1, 2024 Risk: medium
  Aileron Therapeutics, Inc. announced on February 29, 2024, that its Board of Directors has appointed Dr. Christopher P. Miller as Chief Medical Officer. Dr. Mil
• Aileron Therapeutics Files 8-K on Governance and Compensation Changes — Feb 29, 2024 Risk: medium
  Aileron Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting on various corporate governance matters. The filing indicates events related to the depa
• Aileron Therapeutics Reports Officer/Director Changes — Feb 13, 2024 Risk: medium
  Aileron Therapeutics, Inc. filed an 8-K on February 13, 2024, reporting an event that occurred on February 9, 2024. The filing indicates changes related to the
• Aileron Therapeutics Updates Corporate Address in 8-K Filing — Jan 29, 2024
  Aileron Therapeutics, Inc. (ALRN) filed an 8-K on January 29, 2024, to update its corporate information, specifically its business and mailing address to 738 Ma
• Aileron Therapeutics Files Routine 8-K on Jan 25, 2024 — Jan 25, 2024
  Aileron Therapeutics, Inc. filed an 8-K on January 25, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing indicates t
• Aileron Therapeutics Faces Nasdaq Delisting, Changes Auditor — Jan 10, 2024
  Aileron Therapeutics, Inc. (ALRN) filed an 8-K on January 10, 2024, reporting two significant events from January 4, 2024: a notice of delisting from The Nasdaq

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX